Similar articles

• Studies on the betacellulin receptor in pancreatic AR42J cells.

  Ishiyama N, Kanzaki M, Seno M, Yamada H, Kobayashi I, Kojima I. Ishiyama N, et al. Diabetologia. 1998 Jun;41(6):623-8. doi: 10.1007/s001250050959. Diabetologia. 1998. PMID: 9662041
• Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.

  Wiedmann M, Feisthammel J, Blüthner T, Tannapfel A, Kamenz T, Kluge A, Mössner J, Caca K. Wiedmann M, et al. Anticancer Drugs. 2006 Aug;17(7):783-95. doi: 10.1097/01.cad.0000217433.48870.37. Anticancer Drugs. 2006. PMID: 16926628
• Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.

  Komurasaki T, Toyoda H, Uchida D, Morimoto S. Komurasaki T, et al. Oncogene. 1997 Dec 4;15(23):2841-8. doi: 10.1038/sj.onc.1201458. Oncogene. 1997. PMID: 9419975
• The ErbB/HER family of protein-tyrosine kinases and cancer.

  Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Pharmacol Res. 2014. PMID: 24269963 Review.
• Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer.

  Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N. Tokunaga A, et al. Cancer. 1995 Mar 15;75(6 Suppl):1418-25. doi: 10.1002/1097-0142(19950315)75:6+<1418::aid-cncr2820751505>3.0.co;2-y. Cancer. 1995. PMID: 7889468 Review.